Acceleron Pharma Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$141.7M
Industry:Pharma
Founded:2004
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Acceleron Pharma's estimated annual revenue is currently $62.1M per year.
  • Acceleron Pharma received $264.5M in venture funding in January 2019.
  • Acceleron Pharma's estimated revenue per employee is $201,000
  • Acceleron Pharma's total funding is $141.7M.

Employee Data

  • Acceleron Pharma has 309 Employees.
  • Acceleron Pharma grew their employee count by 13% last year.
  • Acceleron Pharma currently has 35 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
N/A445N/AN/A-N/A
#2
N/A411N/AN/A-N/A
#3
$43.8M218N/AN/A-N/A
#4
$1737.8M8646N/AN/A-N/A
#5
$26.1M130N/AN/A-N/A
#6
$30.3M38550%N/A-N/A
#7
$5.4M27N/AN/A-N/A
#8
$780.7M3884N/AN/A-N/A
#9
$20.5M102N/AN/A-N/A
#10
$17.3M8648%N/A-N/A
Missing a competitor? Contribute!?
Submit

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

keywords:Biotechnology,Cleantech,E-Commerce,Healthcare,Pharmaceuticals,Wind Power

309

Number of Employees

$62.1M

Revenue (est)

35

Current Jobs

13%

Employee Growth %

$141.7M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Acceleron Pharma News

09/03/2019 - Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?

In 2016 Habib Dable was appointed CEO of Acceleron Pharma Inc. (NASDAQ:XLRN). This report will, first, examine the CEO compensation ...

09/08/2019 - Finding The Floor And Ceiling Of Acceleron Pharma Inc. (XLRN)

On August 19, 2019, Acceleron Pharma Inc. (NASDAQ:XLRN) shares gained 1.11% or 0.51 points to close at $46.51 with a thin trading volume ...

09/03/2019 - Acceleron Pharma Inc (NASDAQ:XLRN) Shares Sold by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. cut its stake in Acceleron Pharma Inc (NASDAQ:XLRN) by 20.5% in the second ...

}

Acceleron Pharma Funding

DateAmountRoundLead InvestorsReference
2004-02-16$25.0M1stPolaris Venture PartnersArticle
2006-01-06$8.0MUndisclosedHercules Technology Growth CapArticle
2006-08-03$30.0MBOrbiMed AdvisorsArticle
2007-10-31$31.0MCBessemer Venture PartnersArticle
2011-12-27$30.0MUndisclosedCelgeneArticle
2014-01-22$100.0MUndisclosedCitigroupArticle
2017-09-22$230.0MUndisclosedJ.P. Morgan Securities LLCArticle
2019-01-17$264.5MUndisclosedCitigroupArticle

Acceleron Pharma Executive Hires

DateNameTitleReference
2006-05-17Matthew L. ShermanChief Medical OfficerArticle
2007-03-30Robert SteiningerSVP ManufacturingArticle
2007-04-26James DesiderioVP Program MgmtArticle
2007-09-19John L. KnopfCEOArticle
2007-09-25Niels BorgsteinVP Medical ResearchArticle
2009-12-23Melissa MorandiVP QualityArticle
2010-12-01Kevin F. McLaughlinSVP/CFOArticle
2015-03-09Steven ErtelEVP/COOArticle
2015-04-07Francois NaderChairmanArticle
2017-05-03Steven ErtelSpecial AadvisorArticle
2018-02-09Sujay KangoChief Commercial OfficerArticle
2018-07-06Robert ZeldinChief Medical OfficerArticle

Acceleron Pharma Staff Cuts

DateNumber of EmployeesLocationReference
2010-11-0357 EmployeesArticle